Načítá se...
Chimeric antigen receptor T cell therapies for multiple myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/rela...
Uloženo v:
| Vydáno v: | J Hematol Oncol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6873434/ https://ncbi.nlm.nih.gov/pubmed/31752943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0823-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|